Literature DB >> 6306912

Two types of glycoprotein precursors are produced by the simian rotavirus SA11.

B L Ericson, D Y Graham, B B Mason, H H Hanssen, M K Estes.   

Abstract

The rotavirus genome codes for two glycoproteins: an outer capsid structural glycoprotein (VP7, apparent molecular weight 38,000 (38K)) and a nonstructural glycoprotein (NS28K). The synthesis of these glycoproteins was analyzed in infected cells and in a cell-free system derived from rabbit reticulocyte lysates supplemented with dog pancreatic microsomes. The data showed a 37K product synthesized in the cell-free system is the precursor to the 38K glycoprotein and that the 37K polypeptide contains a cleavable signal sequence (apparent molecular weight 1.5K). The 37K polypeptide was glycosylated in vitro in the presence of microsomal membranes to a polypeptide of 38K that was immunoprecipitated by monospecific antiserum to VP7. Endo H digestion of the 38K polypeptides from either infected cells or the cell-free system produced polypeptides of identical molecular weight, 35.5K (the glycoprotein precursor lacking the signal sequence). These results were confirmed by comparative studies with a variant of SA11 that is defective in glycosylation of VP7. Similar experiments with the 20K precursor to the 29K nonstructural glycoprotein showed the 20K polypeptide contains a noncleavable signal sequence. Both glycoproteins were inserted into microsomal membranes and were processed via oligosaccharide trimming.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6306912     DOI: 10.1016/0042-6822(83)90147-2

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  31 in total

1.  Multiple glycoproteins synthesized by the smallest RNA segment (S10) of bluetongue virus.

Authors:  X Wu; S Y Chen; H Iwata; R W Compans; P Roy
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

2.  The cellular secretory pathway is not utilized for biosynthesis, modification, or intracellular transport of the simian virus 40 large tumor antigen.

Authors:  D L Jarvis; W K Chan; M K Estes; J S Butel
Journal:  J Virol       Date:  1987-12       Impact factor: 5.103

3.  Processing of rotavirus glycoprotein VP7: implications for the retention of the protein in the endoplasmic reticulum.

Authors:  S C Stirzaker; P L Whitfeld; D L Christie; A R Bellamy; G W Both
Journal:  J Cell Biol       Date:  1987-12       Impact factor: 10.539

4.  Rotavirus YM gene 4: analysis of its deduced amino acid sequence and prediction of the secondary structure of the VP4 protein.

Authors:  S López; I López; P Romero; E Méndez; X Soberón; C F Arias
Journal:  J Virol       Date:  1991-07       Impact factor: 5.103

5.  Rotavirus protein rearrangements in purified membrane-enveloped intermediate particles.

Authors:  M S Poruchynsky; P H Atkinson
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

6.  Epitope mapping and use of epitope-specific antisera to characterize the VP5* binding site in rotavirus SA11 NSP4.

Authors:  Joseph M Hyser; Carl Q-Y Zeng; Zanna Beharry; Timothy Palzkill; Mary K Estes
Journal:  Virology       Date:  2007-12-31       Impact factor: 3.616

7.  Priming for rotavirus neutralizing antibodies by a VP4 protein-derived synthetic peptide.

Authors:  C F Arias; G Garcia; S Lopez
Journal:  J Virol       Date:  1989-12       Impact factor: 5.103

Review 8.  Rotavirus gene structure and function.

Authors:  M K Estes; J Cohen
Journal:  Microbiol Rev       Date:  1989-12

9.  Rotavirus neutralizing protein VP7: antigenic determinants investigated by sequence analysis and peptide synthesis.

Authors:  P R Gunn; F Sato; K F Powell; A R Bellamy; J R Napier; D R Harding; W S Hancock; L J Siegman; G W Both
Journal:  J Virol       Date:  1985-06       Impact factor: 5.103

10.  Primary structure of the neutralization antigen of simian rotavirus SA11 as deduced from cDNA sequence.

Authors:  C F Arias; S López; J R Bell; J H Strauss
Journal:  J Virol       Date:  1984-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.